Wegovy’s Pill Expands Novo Nordisk’s Reach—but the Cardiovascular Lead Has Limits

Wegovy’s once-daily pill gives Novo Nordisk a way to reach people who do not want injections and has quickly become a major test of the company’s position in obesity care. The U.S. launch began on January 5, 2026, and Novo later reported more than 3 million prescriptions in just over five months. 58

The opportunity is substantial, but the evidence needs to be separated carefully. SELECT provides strong randomized evidence for semaglutide’s cardiovascular benefit, while STEER is a real-world comparison with tirzepatide that suggests an advantage without proving one. At the same time, access, pricing, competition and patent exposure will determine how much of the pill’s clinical promise becomes durable growth for Novo Nordisk.

Where Wegovy’s pill has launched

The pill first became available in the United States, where the starting dose was distributed through more than 70,000 pharmacies and selected telehealth providers. Cash prices began at $149 per month and reached as high as $299 for higher doses. 10

The early U.S. prescription trajectory was strong. Analysts citing IQVIA data reported 18,410 prescriptions in the first full week and 26,109 in the second full week after launch. 46 Novo subsequently announced that the pill had exceeded 3 million prescriptions since its U.S. introduction. 78

Europe followed in stages:

• The United Kingdom became the first European market where patients could access the pill after regulatory approval in June 2026.
• The European Commission approved the once-daily oral treatment for weight management across the European Union on July 15, making it the first oral GLP-1 weight-loss treatment cleared across the bloc.
• Germany became the first EU country to launch the pill, on September 1, 2026.

The European Commission authorization covers adults with obesity, or adults who are overweight and have at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity.

What the German launch means for access and price

Germany is strategically important because it is the largest pharmaceutical market in the European Union. The launch gives Novo an early commercial foothold in a large market while the company prepares additional European rollouts.

An official German tablet price is not established in the evidence reviewed. Reports indicate that the pill is expected to be priced broadly in line with injectable Wegovy, with pharmacy prices for the injection reported at approximately €170 to €280 depending on dosage. That would still leave the treatment as a substantial monthly expense for many patients.

The German launch therefore expands availability, but it does not automatically guarantee broad access. Reimbursement rules, prescribing criteria and patients’ willingness to pay will be as important as regulatory approval in determining uptake.

The “90%” figure is about payment, not market share

A frequently repeated 90% figure needs clarification. Novo’s U.S. executive said direct-to-consumer purchases represented about 90% of Wegovy pill volume, compared with about 30% of injectable GLP-1 weight-loss volume. 3

That does not establish that the pill holds 90% of the entire oral obesity-drug market. It shows instead that most early pill users were paying directly rather than relying on insurance. This helps explain the product’s rapid launch: patients can access it through cash-pay channels, telehealth providers and pharmacies. But it also exposes the business to affordability limits and possible interruptions in treatment.

Broader reimbursement could expand the eligible population considerably. Research on Medicare found that Wegovy prescriptions increased after coverage became available for reducing cardiovascular risk, although only a small fraction of potentially eligible beneficiaries received the drug. 2

What SELECT shows about cardiovascular benefit

SELECT is the stronger part of Wegovy’s cardiovascular case. It was a multicenter, randomized, double-blind, placebo-controlled outcomes trial evaluating semaglutide 2.4 mg alongside standard cardiovascular care. The study enrolled adults with established cardiovascular disease, overweight or obesity, and no prior diabetes. 18

The trial found that semaglutide reduced major adverse cardiovascular events by 20% compared with placebo. The endpoint included cardiovascular death, non-fatal heart attack and non-fatal stroke. 1

The result helped support the FDA’s cardiovascular-risk-reduction indication for Wegovy—the first U.S. obesity-drug indication specifically aimed at reducing these serious cardiovascular events. 1

That matters commercially because it broadens the value proposition beyond weight loss. For eligible patients, clinicians and payers can assess Wegovy not only as an obesity treatment but also as a therapy associated with lower cardiovascular-event risk. It may also support coverage decisions where insurers are more willing to reimburse prevention of costly complications than weight loss alone.

One important qualification is that the core SELECT evidence concerns injectable semaglutide 2.4 mg. The pill uses the same active ingredient, and Novo’s U.S. approval announcement included cardiovascular-risk reduction, but SELECT should not be described as a direct pill-versus-placebo cardiovascular trial. 918

What STEER shows against tirzepatide

STEER addresses a different question: how semaglutide performed against tirzepatide in routine clinical practice. The study was an observational real-world analysis, not a randomized head-to-head cardiovascular-outcomes trial.

In the published analysis, semaglutide was associated with a 29% lower risk of a three-component recurrent major cardiovascular-event measure and a 22% lower risk of a five-component measure compared with tirzepatide. In a treatment-adherent analysis, the reduction for the three-component composite was reported as 57%. 17

Those findings are commercially useful for Novo Nordisk because they support a cardiovascular-differentiation narrative against Eli Lilly’s tirzepatide products. But they do not establish that Wegovy is causally superior to tirzepatide. Patients receiving the two drugs may differ in underlying risk, prescribing patterns, treatment persistence and access. The follow-up period and treatment-gap definitions also affect the comparison.

The most defensible conclusion is that STEER strengthens the case for further comparative research. SELECT demonstrates a randomized cardiovascular benefit versus placebo; STEER provides encouraging, real-world comparative evidence, but not the same level of proof as a randomized trial.

Why the pill matters to Novo Nordisk—and Denmark

The pill adds a second delivery format to Novo’s obesity franchise and could expand the market to people who resist needles. Its early prescription growth also gives Novo a new volume driver at a time when investors are closely comparing the company with Lilly.

The impact reaches beyond the company. Denmark raised its 2026 GDP-growth forecast to 3.7% from 2.7%, attributing the increase mainly to a larger-than-expected contribution from Novo Nordisk’s new weight-loss pill.

That macroeconomic benefit should not be confused with a guarantee of stronger shareholder returns. Novo’s outlook has remained sensitive to execution. In August, the company raised its full-year forecast, but investors focused on a narrow Wegovy pill sales miss and a setback for its next-generation obesity drug CagriSema.

Insurance coverage is the biggest growth lever

The early U.S. sales mix shows both demand and constraint. If most patients pay directly, the product can grow quickly among people who can afford it, but the addressable market is narrower than the total number of medically eligible patients.

The FDA cardiovascular indication creates a clearer basis for coverage among eligible patients with established cardiovascular disease. Medicare prescription growth after cardiovascular-risk coverage began suggests that reimbursement can materially change utilization, even though access remained limited relative to the potential eligible population. 2

More commercial and public-insurance coverage could increase prescription volumes, improve continuity of treatment and make the pill’s convenience more valuable. The trade-off is that larger payer access commonly brings negotiations, rebates and pressure on realized prices. More patients would not necessarily translate into proportionally higher margins.

Competition and patent risk remain central

Wegovy’s pill arrived with an early lead, but that lead is not secure. Tirzepatide remains a major competitor, and other oral incretin treatments could make the needle-free category more crowded.

Novo also faces pricing pressure. The company warned in February that unprecedented price pressure could contribute to 2026 sales and profit declines of as much as 13%; the warning was followed by a loss of nearly $50 billion in market value.

Patent exposure adds a second medium-term risk. Reporting in August indicated that generic competition for Wegovy, previously expected in 2026, was shifting toward 2027 rather than disappearing. Delaying generic pressure gives Novo more time to build the pill’s patient base, but it does not remove the eventual threat to price and market share.

The investment conclusion

The optimistic case is that oral convenience, international launches, cardiovascular differentiation and broader insurance coverage allow Wegovy to reach many more patients before generic semaglutide arrives. SELECT gives Novo a durable evidence base that goes beyond weight loss, while STEER offers supportive comparative data against tirzepatide.

The cautious case is that cash-pay dependence limits access, payer rebates reduce net prices, Lilly and newer entrants narrow the competitive gap, and generic competition eventually compresses revenue and margins.

Wegovy’s pill is therefore a meaningful expansion of Novo Nordisk’s obesity platform—not a guarantee of lasting dominance. SELECT supports the cardiovascular moat. STEER strengthens the competitive story, but its observational design means it should be treated as suggestive rather than definitive evidence that semaglutide is superior to tirzepatide.